Cyclooxygenase-2 in Synaptic Signaling
Open accessThe DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
Cyclooxygenase-2 (COX-2), a rate-limiting enzyme converting arachidonic acid to prostaglandins and a key player in neuroinflammation, has been implicated in the pathogenesis of neurodegenerative diseases such as multiple sclerosis, Parkinson's and Alzheimer's diseases, and in traumatic brain injury- and ischemia-induced neuronal damage, and epileptogenesis. Accumulated information suggests that the contribution of COX-2 to neuropathology is associated with its involvement in synaptic modification. Inhibition or elevation of COX-2 has been shown to suppress or enhance excitatory glutamatergic neurotransmission and long-term potentiation (LTP). These events are mainly mediated via PGE(2), the predominant reaction product of COX-2, and the PGE(2) subtype 2 receptor (EP(2))-protein kinase A pathway. Recent evidence shows that endogenous cannabinoids are substrates for COX-2 and can be oxygenated by COX-2 to form new classes of prostaglandins (prostaglandin glycerol esters and prostaglandin ethanolamides). These COX-2 oxidative metabolites of endocannabinoids, as novel signaling mediators, modulate synaptic transmission and plasticity and cause neurodegeneration. The actions of these COX-2 metabolites are likely mediated by mitogen-activated protein kinase (MAPK) and inositol 1,4,5-trisphosphate (IP(3)) signal transduction pathways. These discoveries suggest that the contributions of COX-2 to neurotransmission and brain malfunction result not only from its conversion of arachidonic acid to classic prostaglandins but also from its oxidative metabolism of endocannabinoids to novel prostaglandins. Thus, elucidation of COX-2 in synaptic signaling may provide a mechanistic basis for designing new drugs aimed at preventing, treating or alleviating neuroinflammation-associated neurological disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“COX-2 overexpression increases PGE-2 resulting in glutamatergic excitability, stimulation of corticotropin-releasing hormone, and the release of pro-inflammatory cytokines (159).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [159]
In the citing paper
“blocking COX-2 will limit the production of the active oxidative metabolites of AEA (prostaglandin-Gs) and 2-AG (prostaglandin-EAs), that are posited to exert their own effects at as yet to be determined receptors (Hu et al., 2008; Sang et al., 2006; Yang and Chen, 2008).”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Yang and Chen, 2008
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566 · cited 1×
“Also COX-2 expression is upregulated by high-frequency stimulation (HFS) associated with the induction of long-term potentiation (LTP), a form of synaptic plasticity and cellular model of learning and memory [16].”
BackgroundInhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“and is present in various mammalian tissues, mostly in the central nervous system, while the CB2 was identified by sequence homology in 1993 [75], and is most abundant in the immune system.”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 1×
“The CB1 cannabinoid receptor was molecularly cloned from rat brain in 1990 [74], Yang and Chen Page 5”
MethodMechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,734
Prostanoid Receptors: Structures, Properties, and Functions
Narumiya, S., Sugimoto, Y., & Ushikubi, F. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1193 · Cited by 2,412
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989
Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2
Smith, W. L., Garavito, R. M., & DeWitt, D. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33157 · Cited by 1,978
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“While virodhamine, 2AGE and NADA are a partial or weak agonist for the CB1 or CB2 receptor, and their physiology and pharmacology have not yet been clarified [70,71,90], AEA and 2-AG are the two most studied eCBs and have been demonstrated to be involved in a variety of physiological and pathological processes in mamm…”
BackgroundKujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W., & Herschman, H. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98774-0 · Cited by 1,789
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons, D. L., Botting, R. M., & Hla, T. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.3 · Cited by 1,693
Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607
Role of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Hla, T., & Neilson, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7384 · Cited by 1,465
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Endocannabinoid Signaling in the Brain
Wilson, R. I., & Nicoll, R. A. (2002) · Science · doi:10.1126/science.1063545 · Cited by 1,260
Yamagata, K., Andreasson, K. I., Kaufmann, W. E., Barnes, C. A., & Worley, P. F. (1993) · Neuron · doi:10.1016/0896-6273(93)90192-t · Cited by 1,226
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208
Sugimoto, Y., & Narumiya, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r600038200 · Cited by 1,196
Hawkey, C. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12154-2 · Cited by 1,173
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Prostanoid Receptors: Subtypes and Signaling
Breyer, R. M., Bagdassarian, C. K., Myers, S. A., & Breyer, M. D. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.661 · Cited by 1,011 · cited 1×
“EP3 is associated with a pertussis toxin (PTX)-sensitive Gi protein resulting in a decrease of cAMP [51,58].”
BackgroundHuang, S. M., Bisogno, T., Trevisani, M., Al-Hayani, A., De Petrocellis, L., Fezza, F., Tognetto, M., Petros, T. J., Krey, J. F., Chu, C. J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122196999 · Cited by 964
Kreitzer, A. C., & Regehr, W. G. (2001) · Neuron · doi:10.1016/s0896-6273(01)00246-x · Cited by 875
cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.
O'Banion, M. K., Winn, V. D., & Young, D. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.4888 · Cited by 821
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain
Gong, J.-P., Onaivi, E. S., Ishiguro, H., Liu, Q.-R., Tagliaferro, P. A., Brusco, A., & Uhl, G. R. (2006) · Brain Research · doi:10.1016/j.brainres.2005.11.035 · Cited by 820
ENDOCANNABINOID-MEDIATED SYNAPTIC PLASTICITY IN THE CNS
Chevaleyre, V., Takahashi, K. A., & Castillo, P. E. (2006) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.112834 · Cited by 783
Cyclooxygenase-2 (COX-2) in Inflammatory and Degenerative Brain Diseases
Minghetti, L. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.9.901 · Cited by 779
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanuš, L., Breuer, A., Mechoulam, R., & Shohami, E. (2001) · Nature · doi:10.1038/35097089 · Cited by 752
Cannabinoid receptors and pain
Pertwee, R. G. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00031-9 · Cited by 741
Porter, A. C., Sauer, J.-M., Knierman, M. D., Becker, G. W., Berna, M. J., Bao, J., Nomikos, G. G., Carter, P., Bymaster, F. P., Leese, A. B., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1020 · Cited by 615
Cannabinoid physiology and pharmacology: 30 years of progress
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608
Anandamide and vanilloid TRPV1 receptors
Ross, R. A. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705467 · Cited by 604
Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids
E. Alger, B. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00080-1 · Cited by 598
Kaufmann, W. E., Worley, P. F., Pegg, J., Bremer, M., & Isakson, P. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2317 · Cited by 593
Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons
Twitchell, W., Brown, S., & Mackie, K. (1997) · Journal of Neurophysiology · doi:10.1152/jn.1997.78.1.43 · Cited by 544
Presynaptic Specificity of Endocannabinoid Signaling in the Hippocampus
Wilson, R. I., Kunos, G., & Nicoll, R. A. (2001) · Neuron · doi:10.1016/s0896-6273(01)00372-5 · Cited by 544
Namba, T., Sugimoto, Y., Negishi, M., Irie, A., Ushikubi, F., Kakizuka, A., Ito, S., Ichikawa, A., & Narumiya, S. (1993) · Nature · doi:10.1038/365166a0 · Cited by 543
Inflammation and the Degenerative Diseases of Aging
McGEER, P. L., & McGEER, E. G. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.007 · Cited by 518
Molecular Composition of the Endocannabinoid System at Glutamatergic Synapses
Katona, I., Urbán, G. M., Wallace, M., Ledent, C., Jung, K.-M., Piomelli, D., Mackie, K., & Freund, T. F. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0309-06.2006 · Cited by 511
CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
Mackie, K. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141254 · Cited by 505
Melis, M., Pistis, M., Perra, S., Muntoni, A. L., Pillolla, G., & Gessa, G. L. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4503-03.2004 · Cited by 478
Eljaschewitsch, E., Witting, A., Mawrin, C., Lee, T., Schmidt, P. M., Wolf, S., Hoertnagl, H., Raine, C. S., Schneider-Stock, R., Nitsch, R., et al. (2006) · Neuron · doi:10.1016/j.neuron.2005.11.027 · Cited by 445
Iadecola, C., Niwa, K., Nogawa, S., Zhao, X., Nagayama, M., Araki, E., Morham, S., & Ross, M. E. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1294 · Cited by 411
Synthesis of Prostaglandin E2 Ethanolamide from Anandamide by Cyclooxygenase-2
Yu, M., Ives, D., & Ramesha, C. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21181 · Cited by 404
Kozak, K. R., Rowlinson, S. W., & Marnett, L. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007088200 · Cited by 390
CANNABINOID RECEPTORS AND THEIR ENDOGENOUS AGONISTS
Felder, C. C., & Glass, M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.179 · Cited by 390
BISOGNO, T., MELCK, D., BOBROV, M. Y., GRETSKAYA, N. M., BEZUGLOV, V. V., De PETROCELLIS, L., & Di MARZO, V. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510817 · Cited by 381
Skaper, S. D., Buriani, A., Dal Toso, R., Petrelli, L., Romanello, S., Facci, L., & Leon, A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3984 · Cited by 377
Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway
Murakami, M., & Kudo, I. (2004) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00037-7 · Cited by 371
Kozak, K. R., Crews, B. C., Morrow, J. D., Wang, L.-H., Ma, Y. H., Weinander, R., Jakobsson, P.-J., & Marnett, L. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206788200 · Cited by 368
Gaoni, Y., & Mechoulam, R. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00730a036 · Cited by 364
Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., & Izzo, A. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02327.x · Cited by 361
Murakami, M., Nakashima, K., Kamei, D., Masuda, S., Ishikawa, Y., Ishii, T., Ohmiya, Y., Watanabe, K., & Kudo, I. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305108200 · Cited by 344
Nakayama, M., Uchimura, K., Zhu, R. L., Nagayama, T., Rose, M. E., Stetler, R. A., Isakson, P. C., Chen, J., & Graham, S. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10954 · Cited by 337
Cannabinoids and neuroinflammation
Walter, L., & Stella, N. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705667 · Cited by 336
Carrier, E. J., Kearn, C. S., Barkmeier, A. J., Breese, N. M., Yang, W., Nithipatikom, K., Pfister, S. L., Campbell, W. B., & Hillard, C. J. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.4.999 · Cited by 336
Yoshida, T., Fukaya, M., Uchigashima, M., Miura, E., Kamiya, H., Kano, M., & Watanabe, M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0054-06.2006 · Cited by 327
Marsicano, G., Moosmann, B., Hermann, H., Lutz, B., & Behl, C. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00716.x · Cited by 315
Production of nitric oxide by glial cells: Regulation and potential roles in the CNS
Murphy, S. (2000) · Glia · doi:10.1002/(sici)1098-1136(20000101)29:1<1::aid-glia1>3.0.co;2-n · Cited by 314
Ahmadi, S., Lippross, S., Neuhuber, W. L., & Zeilhofer, H. U. (2002) · Nature Neuroscience · doi:10.1038/nn778 · Cited by 312
Brock, T. G., McNish, R. W., & Peters-Golden, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11660 · Cited by 304
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes
Boie, Y., Stocco, R., Sawyer, N., Slipetz, D. M., Ungrin, M. D., Neuschäfer-Rube, F., Püschel, G. P., Metters, K. M., & Abramovitz, M. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01383-6 · Cited by 296
Cyclooxygenase-2 Regulates Prostaglandin E2Signaling in Hippocampal Long-Term Synaptic Plasticity
Chen, C., Magee, J. C., & Bazan, N. G. (2002) · Journal of Neurophysiology · doi:10.1152/jn.2002.87.6.2851 · Cited by 294
Self-citationMiettinen, S., Fusco, F. R., Yrjänheikki, J., Keinänen, R., Hirvonen, T., Roivainen, R., Närhi, M., Hökfelt, T., & Koistinaho, J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6500 · Cited by 278
Diana, M. A., & Marty, A. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705726 · Cited by 265
Endocannabinoids Control the Induction of Cerebellar LTD
Safo, P. K., & Regehr, W. G. (2005) · Neuron · doi:10.1016/j.neuron.2005.09.020 · Cited by 263
Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases?
Croxford, J. L., & Yamamura, T. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.04.023 · Cited by 255
Effects of Cannabinoids on Neurotransmission
Szabo, B., & Schlicker, E. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_11 · Cited by 252
Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells
Puffenbarger, R. A., Boothe, A. C., & Cabral, G. A. (2000) · Glia · doi:10.1002/(sici)1098-1136(20000101)29:1<58::aid-glia6>3.0.co;2-w · Cited by 248
Bazan, N. G. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r300013-jlr200 · Cited by 247
Bastien, L., Sawyer, N., Grygorczyk, R., Metters, K. M., & Adam, M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32654-6 · Cited by 246
Sheng, W. S., Hu, S., Min, X., Cabral, G. A., Lokensgard, J. R., & Peterson, P. K. (2005) · Glia · doi:10.1002/glia.20108 · Cited by 245
Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease
Ho, L., Pieroni, C., Winger, D., Purohit, D. P., Aisen, P. S., & Pasinetti, G. M. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990801)57:3<295::aid-jnr1>3.0.co;2-0 · Cited by 244
Deadwyler, S. A., Hampson, R. E., Mu, J., Whyte, A., & Childers, S. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09495-9 · Cited by 241
Cannabinoid receptors in microglia of the central nervous system: immune functional relevance
Cabral, G. A., & Marciano-Cabral, F. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0405216 · Cited by 240
Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus
Kim, J., & Alger, B. E. (2004) · Nature Neuroscience · doi:10.1038/nn1262 · Cited by 238
Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus
Makara, J. K., Mor, M., Fegley, D., Szabó, S. I., Kathuria, S., Astarita, G., Duranti, A., Tontini, A., Tarzia, G., Rivara, S., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1521 · Cited by 232
Age-Dependent Cognitive Deficits and Neuronal Apoptosis in Cyclooxygenase-2 Transgenic Mice
Andreasson, K. I., Savonenko, A., Vidensky, S., Goellner, J. J., Zhang, Y., Shaffer, A., Kaufmann, W. E., Worley, P. F., Isakson, P., & Markowska, A. L. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-20-08198.2001 · Cited by 231
Direct Activation of Rat Spinal Dorsal Horn Neurons by Prostaglandin E2
Baba, H., Kohno, T., Moore, K. A., & Woolf, C. J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01750.2001 · Cited by 228
Hewett, S. J., Uliasz, T. F., Vidwans, A. S., & Hewett, J. A. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39251-1 · Cited by 227
Cannabinoid signaling in glial cells
Stella, N. (2004) · Glia · doi:10.1002/glia.20084 · Cited by 219
Nociception in cyclooxygenase isozyme-deficient mice
Ballou, L. R., Botting, R. M., Goorha, S., Zhang, J., & Vane, J. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180319297 · Cited by 205
Depolarization‐induced suppression of excitation in murine autaptic hippocampal neurones
Straiker, A., & Mackie, K. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.091918 · Cited by 201
The endocannabinoid signalling system: Biochemical aspects
BISOGNO, T., LIGRESTI, A., & DIMARZO, V (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.027 · Cited by 201
Lipid signaling: Sleep, synaptic plasticity, and neuroprotection
Chen, C., & Bazan, N. G. (2005) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2005.07.001 · Cited by 196
Self-citationPitier, T. A., & Alger, B. E. (1994) · Neuron · doi:10.1016/0896-6273(94)90430-8 · Cited by 195
Sang, N., Zhang, J., Marcheselli, V., Bazan, N. G., & Chen, C. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2392-05.2005 · Cited by 192
Self-citationCannabinoid Receptors and Their Role in Neuroprotection
van der Stelt, M., & Di Marzo, V. (2005) · NeuroMolecular Medicine · doi:10.1385/nmm:7:1-2:037 · Cited by 189
Zonta, M., Sebelin, A., Gobbo, S., Fellin, T., Pozzan, T., & Carmignoto, G. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.046706 · Cited by 186
Khaspekov, L. G., Brenz Verca, M. S., Frumkina, L. E., Hermann, H., Marsicano, G., & Lutz, B. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03285.x · Cited by 184
CB1 cannabinoid receptors are involved in neuroprotection via NF-κB inhibition
Panikashvili, D., Mechoulam, R., Beni, S. M., Alexandrovich, A., & Shohami, E. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600047 · Cited by 181
Claveau, D., Sirinyan, M., Guay, J., Gordon, R., Chan, C.-C., Bureau, Y., Riendeau, D., & Mancini, J. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.9.4738 · Cited by 180
Sullivan, J. M. (2000) · Learning & Memory · doi:10.1101/lm.7.3.132 · Cited by 173
Guzmán, M., Sánchez, C., & Galve-Roperh, I. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00256-5 · Cited by 161
CB1 and CB2 receptor-mediated signalling: a focus on endocannabinoids
McAllister, S. D., & Glass, M. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0344 · Cited by 159
Post-Training Cyclooxygenase-2 (COX-2) Inhibition Impairs Memory Consolidation
Teather, L. A., Packard, M. G., & Bazan, N. G. (2002) · Learning & Memory · doi:10.1101/lm.43602 · Cited by 147
New insights into COX-2 biology and inhibition
Patrignani, P., Tacconelli, S., Sciulli, M. G., & Capone, M. L. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.12.024 · Cited by 146
Chen, C., & Bazan, N. G. (2005) · Journal of Neurophysiology · doi:10.1152/jn.00696.2004 · Cited by 144
Self-citationProstaglandin E Synthase: A Novel Drug Target for Inflammation and Cancer
Murakami, M., & Kudo, I. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206776055912 · Cited by 143
Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptide
Milton, N. G. N. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00936-9 · Cited by 141
Identification of prostaglandin E receptor ‘EP2’ cloned from mastocytoma cells as EP4 subtype
Nishigaki, N., Negishi, M., Honda, A., Sugimoto, Y., Namba, T., Narumiya, S., & Ichikawa, A. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00421-5 · Cited by 139
Oxidative Metabolism of Endocannabinoids by COX-2
Kozak, K., Prusakiewicz, J., & Marnett, L. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043453081 · Cited by 136
Function of COX-2 and Prostaglandins in Neurological Disease
Liang, X., Wu, L., Wang, Q., Hand, T. A., Bilak, M. M., McCullough, L. B., & Andreasson, K. I. (2007) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-0058-8 · Cited by 127
COX-2 as a multifunctional neuronal modulator
Bazan, N. G. (2001) · Nature Medicine · doi:10.1038/86477 · Cited by 125
Cannabinoids: Between Neuroprotection and Neurotoxicity
Sarne, Y., & Mechoulam, R. (2005) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/156800705774933005 · Cited by 119
Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels
PETROCELLIS, L. D., & Marzo, V. D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.021 · Cited by 114
Role of COX-2 in Inflammatory and Degenerative Brain Diseases
Minghetti, L. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_5 · Cited by 114
Gopez, J. J., Yue, H., Vasudevan, R., Malik, A. S., Fogelsanger, L. N., Lewis, S., Panikashvili, D., Shohami, E., Jansen, S. A., Narayan, R. K., et al. (2005) · Neurosurgery · doi:10.1227/01.neu.0000154060.14900.8f · Cited by 113
Nirodi, C. S., Crews, B. C., Kozak, K. R., Morrow, J. D., & Marnett, L. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0303950101 · Cited by 113
Alger, B. E., Pitler, T. A., Wagner, J. J., Martin, L. A., Morishita, W., Kirov, S. A., & Lenz, R. A. (1996) · The Journal of Physiology · doi:10.1113/jphysiol.1996.sp021677 · Cited by 110
Hewett, S. J., Bell, S. C., & Hewett, J. A. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.04.011 · Cited by 100
Lipid Signaling and Synaptic Plasticity
Sang, N., & Chen, C. (2006) · The Neuroscientist · doi:10.1177/1073858406290794 · Cited by 99
Self-citationSlanina, K. A., & Schweitzer, P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.04.019 · Cited by 97
Endocannabinoids restrict hippocampal long-term potentiation via CB1
Slanina, K. A., Roberto, M., & Schweitzer, P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.04.021 · Cited by 97
Intrahippocampal infusion of a cyclooxygenase-2 inhibitor attenuates memory acquisition in rats
Rall, J., Mach, S. A., & Dash, P. K. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02248-0 · Cited by 95
Shaw, K. N., Commins, S., & O'Mara, S. M. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02643.x · Cited by 95
Alternative splicing generates multiple isoforms of a rabbit prostaglandin E2 receptor.
BREYER, R. M., Emeson, R. B., Jl, T., Breyer, M. D., Davis, L. S., Abromson, R. M., & Ferrenbach, S. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37583-x · Cited by 93
Sang, N., Zhang, J., & Chen, C. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04668.x · Cited by 90
Self-citationSang, N., Zhang, J., & Chen, C. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.105569 · Cited by 89
Self-citationMurray, H. J., & O'Connor, J. J. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(02)00375-1 · Cited by 85
COX-2 oxidative metabolism of endocannabinoids augments hippocampal synaptic plasticity
Yang, H., Zhang, J., Andreasson, K. I., & Chen, C. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.12.019 · Cited by 72
Self-citationBosetti, F., Langenbach, R., & Weerasinghe, G. R. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02829.x · Cited by 69
Ryanodine Receptor Regulates Endogenous Cannabinoid Mobilization in the Hippocampus
Isokawa, M., & Alger, B. E. (2006) · Journal of Neurophysiology · doi:10.1152/jn.00975.2005 · Cited by 64
Neuronal Overexpression of COX-2 Results in Dominant Production of PGE2 and Altered Fever Response
Vidensky, S., Zhang, Y., Hand, T. A., Goellner, J., Shaffer, A. F., Isakson, P. C., & Andreasson, K. I. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:3:1:15 · Cited by 45
Heterogeneous expression and regulation of hippocampal prostaglandin E2 receptors
Zhu, P., Genc, A., Zhang, X., Zhang, J., Bazan, N. G., & Chen, C. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20597 · Cited by 45
Self-citationAkaneya, Y., & Tsumoto, T. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3028-06.2006 · Cited by 44
Inhibitors of Cyclooxygenases produce Amnesia for a Passive Avoidance Task in the Chick
Hölscher, C. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb01127.x · Cited by 44
A time course analysis of cyclooxygenase-2 suggests a role in spatial memory retrieval in rats
Sharifzadeh, M. S., Tavasoli, M., Soodi, M., Mohammadi-Eraghi, S., Ghahremani, M. H., & Roghani, A. (2005) · Neuroscience Research · doi:10.1016/j.neures.2005.11.004 · Cited by 37
Shibuya, I., Setiadji, S. V., Ibrahim, N., Harayama, N., Maruyama, T., Ueta, Y., & Yamashita, H. (2002) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.2002.00741.x · Cited by 36
Alger, B. E. (2005) · Science s STKE · doi:10.1126/stke.3092005pe51 · Cited by 24
Shibuya, I., Tanaka, K., Uezono, Y., Ueta, Y., Toyohira, Y., Yanagihara, N., Izumi, F., & Yamashita, H. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.02167.x · Cited by 24
Sato, T., Ishida, T., Irifune, M., Tanaka, K., Hirate, K., Nakamura, N., & Nishikawa, T. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.01.011 · Cited by 20
Cited by
Ayala, A., Muñoz, M. F., & Argüelles, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/360438 · Cited by 6,349
“2 previously is generated by the actions of cyclooxygenases on AA [4, 91, 93].”
BackgroundRegulation of Immune Responses by Prostaglandin E2
Kalinski, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101029 · Cited by 1,474
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“COX-2 overexpression increases PGE-2 resulting in glutamatergic excitability, stimulation of corticotropin-releasing hormone, and the release of pro-inflammatory cytokines (159).”
BackgroundChen, C., Liao, J., Xia, Y., Liu, X., Jones, R., Haran, J., McCormick, B., Sampson, T. R., Alam, A., & Ye, K. (2022) · Gut · doi:10.1136/gutjnl-2021-326269 · Cited by 491
Self-citationKubera, M., Obuchowicz, E., Goehler, L., Brzeszcz, J., & Maes, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.08.026 · Cited by 443
Metadata
- Authors
- Yang, H., & Chen, C.
- Affiliations
- Louisiana State University Health Sciences Center New Orleans (US)
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-05-01
- Volume
- 14
- Issue
- 14
- Pages
- 1443-1451
- ISSN
- 1381-6128 (ISSN-L)
- PMC
- PMC2561288
- OpenAlex
- W2083843309
- Cited by
- 195
- References
- 138
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 10 · 2023: 7 · 2022: 10 · 2021: 15 · 2020: 13 · 2019: 5 · 2018: 14 · 2017: 7 · 2016: 9 · 2015: 5 · 2014: 10 · 2013: 10 · 2012: 9
- FWCI
- 12.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS054886)
- National Center for Research Resources (P20RR-16816, P20RR016816)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Keywords
- cyclooxygenase-2, synaptic signaling, prostaglandin E2, endocannabinoids, neuroinflammation, long-term potentiation, glutamatergic neurotransmission, synaptic plasticity, neurodegenerative diseases, traumatic brain injury, ischemic neuronal injury, epileptogenesis, MAPK signaling, IP3 signaling, COX-2 inhibitors
- MeSH terms
- Animals, Humans, Synaptic Transmission, Neuronal Plasticity, Oxidation-Reduction, Synapses, Drug Design, Dinoprostone, Signal Transduction, Receptors, Prostaglandin E, Cyclooxygenase 2, Receptors, Prostaglandin E, EP2 Subtype, Cannabinoid Receptor Modulators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.